Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis

Olivia Lenoir, Marine Milon, Anne Virsolvy, Carole Hénique, Alain Schmitt, Jean Marc Massé, Yuri Kotelevtsev, Masashi Yanagisawa, David J. Webb, Sylvain Richard, Pierre Louis Tharaux

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The endothelin systemhasemerged as a novel target for the treatment of diabetic nephropathy. Endothelin-1 promotes mesangial cell proliferation and sclerosis. However, no direct pathogenic effect of endothelin-1 on podocytes has been shown in vivo and endothelin-1 signaling in podocytes has not been investigated. This study investigated endothelin effects in podocytes during experimental diabetic nephropathy. Stimulation of primary mouse podocytes with endothelin-1 elicited rapid calcium transientsmediated by endothelin type A receptors (ETARs) and endothelin typeB receptors (ETBRs).We then generatedmice with a podocyte-specific double deletion of ETAR and ETBR (NPHS2-Cre3Ednralox/lox×Ednrblox/lox [Pod-ETRKO]). In vitro, treatment with endothelin-1 increased total ß-catenin and phospho-NF-κB expression in wild-type glomeruli, but this effect was attenuated in Pod-ETRKO glomeruli. After streptozotocin injection to induce diabetes, wild-type mice developed mild diabetic nephropathy with microalbuminuria, mesangial matrix expansion, glomerular basement membrane thickening, and podocyte loss, whereas Pod-ETRKO mice presented less albuminuria and were completely protected from glomerulosclerosis and podocyte loss, even when uninephrectomized. Moreover, glomeruli from normal and diabetic Pod-ETRKO mice expressed substantially less total b-catenin and phospho-NF-κB compared with glomeruli from counterpart wild-type mice. This evidence suggests that endothelin-1 drives development of glomerulosclerosis and podocyte loss through direct activation of endothelin receptors and NF-κB and ß-catenin pathways in podocytes. Notably, both the expression and function of the ETBR subtype were found to be important. Furthermore, these results indicate that activation of the endothelin-1 pathways selectively in podocytes mediates pathophysiologic crosstalk that influences mesangial architecture and sclerosis.

Original languageEnglish (US)
Pages (from-to)1050-1062
Number of pages13
JournalJournal of the American Society of Nephrology
Volume25
Issue number5
DOIs
StatePublished - May 1 2014

Fingerprint

Podocytes
Diabetic Nephropathies
Endothelin-1
Catenins
Endothelin Receptors
Endothelin A Receptors
Endothelins
Sclerosis
Endothelin B Receptors
Glomerular Basement Membrane
Albuminuria
Mesangial Cells
Streptozocin
Cell Proliferation
Calcium

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Cite this

Lenoir, O., Milon, M., Virsolvy, A., Hénique, C., Schmitt, A., Massé, J. M., ... Tharaux, P. L. (2014). Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. Journal of the American Society of Nephrology, 25(5), 1050-1062. https://doi.org/10.1681/ASN.2013020195

Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. / Lenoir, Olivia; Milon, Marine; Virsolvy, Anne; Hénique, Carole; Schmitt, Alain; Massé, Jean Marc; Kotelevtsev, Yuri; Yanagisawa, Masashi; Webb, David J.; Richard, Sylvain; Tharaux, Pierre Louis.

In: Journal of the American Society of Nephrology, Vol. 25, No. 5, 01.05.2014, p. 1050-1062.

Research output: Contribution to journalArticle

Lenoir, O, Milon, M, Virsolvy, A, Hénique, C, Schmitt, A, Massé, JM, Kotelevtsev, Y, Yanagisawa, M, Webb, DJ, Richard, S & Tharaux, PL 2014, 'Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis', Journal of the American Society of Nephrology, vol. 25, no. 5, pp. 1050-1062. https://doi.org/10.1681/ASN.2013020195
Lenoir, Olivia ; Milon, Marine ; Virsolvy, Anne ; Hénique, Carole ; Schmitt, Alain ; Massé, Jean Marc ; Kotelevtsev, Yuri ; Yanagisawa, Masashi ; Webb, David J. ; Richard, Sylvain ; Tharaux, Pierre Louis. / Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. In: Journal of the American Society of Nephrology. 2014 ; Vol. 25, No. 5. pp. 1050-1062.
@article{ec73f6dffa2c4be6a6b8a73550de8839,
title = "Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis",
abstract = "The endothelin systemhasemerged as a novel target for the treatment of diabetic nephropathy. Endothelin-1 promotes mesangial cell proliferation and sclerosis. However, no direct pathogenic effect of endothelin-1 on podocytes has been shown in vivo and endothelin-1 signaling in podocytes has not been investigated. This study investigated endothelin effects in podocytes during experimental diabetic nephropathy. Stimulation of primary mouse podocytes with endothelin-1 elicited rapid calcium transientsmediated by endothelin type A receptors (ETARs) and endothelin typeB receptors (ETBRs).We then generatedmice with a podocyte-specific double deletion of ETAR and ETBR (NPHS2-Cre3Ednralox/lox×Ednrblox/lox [Pod-ETRKO]). In vitro, treatment with endothelin-1 increased total {\ss}-catenin and phospho-NF-κB expression in wild-type glomeruli, but this effect was attenuated in Pod-ETRKO glomeruli. After streptozotocin injection to induce diabetes, wild-type mice developed mild diabetic nephropathy with microalbuminuria, mesangial matrix expansion, glomerular basement membrane thickening, and podocyte loss, whereas Pod-ETRKO mice presented less albuminuria and were completely protected from glomerulosclerosis and podocyte loss, even when uninephrectomized. Moreover, glomeruli from normal and diabetic Pod-ETRKO mice expressed substantially less total b-catenin and phospho-NF-κB compared with glomeruli from counterpart wild-type mice. This evidence suggests that endothelin-1 drives development of glomerulosclerosis and podocyte loss through direct activation of endothelin receptors and NF-κB and {\ss}-catenin pathways in podocytes. Notably, both the expression and function of the ETBR subtype were found to be important. Furthermore, these results indicate that activation of the endothelin-1 pathways selectively in podocytes mediates pathophysiologic crosstalk that influences mesangial architecture and sclerosis.",
author = "Olivia Lenoir and Marine Milon and Anne Virsolvy and Carole H{\'e}nique and Alain Schmitt and Mass{\'e}, {Jean Marc} and Yuri Kotelevtsev and Masashi Yanagisawa and Webb, {David J.} and Sylvain Richard and Tharaux, {Pierre Louis}",
year = "2014",
month = "5",
day = "1",
doi = "10.1681/ASN.2013020195",
language = "English (US)",
volume = "25",
pages = "1050--1062",
journal = "Journal of the American Society of Nephrology",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis

AU - Lenoir, Olivia

AU - Milon, Marine

AU - Virsolvy, Anne

AU - Hénique, Carole

AU - Schmitt, Alain

AU - Massé, Jean Marc

AU - Kotelevtsev, Yuri

AU - Yanagisawa, Masashi

AU - Webb, David J.

AU - Richard, Sylvain

AU - Tharaux, Pierre Louis

PY - 2014/5/1

Y1 - 2014/5/1

N2 - The endothelin systemhasemerged as a novel target for the treatment of diabetic nephropathy. Endothelin-1 promotes mesangial cell proliferation and sclerosis. However, no direct pathogenic effect of endothelin-1 on podocytes has been shown in vivo and endothelin-1 signaling in podocytes has not been investigated. This study investigated endothelin effects in podocytes during experimental diabetic nephropathy. Stimulation of primary mouse podocytes with endothelin-1 elicited rapid calcium transientsmediated by endothelin type A receptors (ETARs) and endothelin typeB receptors (ETBRs).We then generatedmice with a podocyte-specific double deletion of ETAR and ETBR (NPHS2-Cre3Ednralox/lox×Ednrblox/lox [Pod-ETRKO]). In vitro, treatment with endothelin-1 increased total ß-catenin and phospho-NF-κB expression in wild-type glomeruli, but this effect was attenuated in Pod-ETRKO glomeruli. After streptozotocin injection to induce diabetes, wild-type mice developed mild diabetic nephropathy with microalbuminuria, mesangial matrix expansion, glomerular basement membrane thickening, and podocyte loss, whereas Pod-ETRKO mice presented less albuminuria and were completely protected from glomerulosclerosis and podocyte loss, even when uninephrectomized. Moreover, glomeruli from normal and diabetic Pod-ETRKO mice expressed substantially less total b-catenin and phospho-NF-κB compared with glomeruli from counterpart wild-type mice. This evidence suggests that endothelin-1 drives development of glomerulosclerosis and podocyte loss through direct activation of endothelin receptors and NF-κB and ß-catenin pathways in podocytes. Notably, both the expression and function of the ETBR subtype were found to be important. Furthermore, these results indicate that activation of the endothelin-1 pathways selectively in podocytes mediates pathophysiologic crosstalk that influences mesangial architecture and sclerosis.

AB - The endothelin systemhasemerged as a novel target for the treatment of diabetic nephropathy. Endothelin-1 promotes mesangial cell proliferation and sclerosis. However, no direct pathogenic effect of endothelin-1 on podocytes has been shown in vivo and endothelin-1 signaling in podocytes has not been investigated. This study investigated endothelin effects in podocytes during experimental diabetic nephropathy. Stimulation of primary mouse podocytes with endothelin-1 elicited rapid calcium transientsmediated by endothelin type A receptors (ETARs) and endothelin typeB receptors (ETBRs).We then generatedmice with a podocyte-specific double deletion of ETAR and ETBR (NPHS2-Cre3Ednralox/lox×Ednrblox/lox [Pod-ETRKO]). In vitro, treatment with endothelin-1 increased total ß-catenin and phospho-NF-κB expression in wild-type glomeruli, but this effect was attenuated in Pod-ETRKO glomeruli. After streptozotocin injection to induce diabetes, wild-type mice developed mild diabetic nephropathy with microalbuminuria, mesangial matrix expansion, glomerular basement membrane thickening, and podocyte loss, whereas Pod-ETRKO mice presented less albuminuria and were completely protected from glomerulosclerosis and podocyte loss, even when uninephrectomized. Moreover, glomeruli from normal and diabetic Pod-ETRKO mice expressed substantially less total b-catenin and phospho-NF-κB compared with glomeruli from counterpart wild-type mice. This evidence suggests that endothelin-1 drives development of glomerulosclerosis and podocyte loss through direct activation of endothelin receptors and NF-κB and ß-catenin pathways in podocytes. Notably, both the expression and function of the ETBR subtype were found to be important. Furthermore, these results indicate that activation of the endothelin-1 pathways selectively in podocytes mediates pathophysiologic crosstalk that influences mesangial architecture and sclerosis.

UR - http://www.scopus.com/inward/record.url?scp=84906542664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906542664&partnerID=8YFLogxK

U2 - 10.1681/ASN.2013020195

DO - 10.1681/ASN.2013020195

M3 - Article

VL - 25

SP - 1050

EP - 1062

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

SN - 1046-6673

IS - 5

ER -